COV Share Price | Covalon Technologies Ltd. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Covalon Technologies Ltd. with Similar Stocks

Theralase Technologies, Inc.Nanalysis Scientific Corp.MedMira, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 4.93% and Operating profit at 17.36% over the last 5 years

With ROE of 8.30%, it has a very attractive valuation with a 2.01 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 48 Million (Micro Cap)

P/E

24.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.54

Return on Equity

7.19%

Price to Book

1.56

Revenue and Profits:

Net Sales:

8 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.99%

6 Months

-34.12%

1 Year

-45.98%

2 Years

33.33%

3 Years

-20.0%

4 Years

-24.32%

5 Years

12.0%

Covalon Technologies Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Covalon Technologies Adjusts Valuation Amid Mixed Financial and Technical Indicators

Covalon Technologies Ltd. has recently experienced a valuation adjustment, moving from a very attractive to an attractive status. This change is based on key financial metrics and reflects a transition in technical trends. The company continues to show positive financial performance amid a complex market landscape.

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.93%

EBIT Growth (5y)

17.36%

EBIT to Interest (avg)

-2.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.56

Sales to Capital Employed (avg)

1.19

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.49%

ROE (avg)

2.47%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.01

EV to EBIT

19.35

EV to EBITDA

13.44

EV to Capital Employed

3.48

EV to Sales

1.28

PEG Ratio

0.10

Dividend Yield

ROCE (Latest)

17.99%

ROE (Latest)

8.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 10.53% vs -7.32% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -75.00% vs -66.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.40",
          "val2": "7.60",
          "chgp": "10.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.10",
          "val2": "0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9.40%",
          "val2": "37.20%",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 17.29% vs 46.96% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 160.00% vs 51.61% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.20",
          "val2": "26.60",
          "chgp": "17.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.10",
          "val2": "-3.60",
          "chgp": "186.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.70",
          "val2": "-4.50",
          "chgp": "160.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "69.00%",
          "val2": "-170.30%",
          "chgp": "23.93%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

8.40

7.60

10.53%

Operating Profit (PBDIT) excl Other Income

0.10

0.50

-80.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.10

0.40

-75.00%

Operating Profit Margin (Excl OI)

-9.40%

37.20%

-4.66%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 10.53% vs -7.32% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -75.00% vs -66.67% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'24

Sep'24

Sep'23

Change(%)

Net Sales

31.20

26.60

17.29%

Operating Profit (PBDIT) excl Other Income

3.10

-3.60

186.11%

Interest

0.10

0.00

Exceptional Items

0.60

0.00

Consolidate Net Profit

2.70

-4.50

160.00%

Operating Profit Margin (Excl OI)

69.00%

-170.30%

23.93%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2024 is 17.29% vs 46.96% in Sep 2023

Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 160.00% vs 51.61% in Sep 2023

All Annual Results

Company CV

About Covalon Technologies Ltd.

Covalon Technologies Ltd.

Pharmaceuticals & Biotechnology

Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of medical products that manage patient outcomes and save lives in the areas of wound care, infection management and surgical procedures. The Company offers platform technologies: Collagen matrix; Antimicrobial silicone adhesive and Medical coating technology. The collagen matrix platform is used to manufacture products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. The antimicrobial silicone adhesive platform is the basis for a range of pre-surgical, post surgical and vascular access products that are designed to kill any bacteria or yeast that comes into contact with the antimicrobial silicone. The coating technology is a grafting from process, which utilizes photo-polymerization to create active grafting sites.

Company Coordinates

Company Details

1660 Tech Ave Unit 5 , MISSISSAUGA ON : L4W 5S7

Tel: 1 905 5688400

http://www.covalon.com/

Registrar Details